Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Republicans Favor Regulatory ‘Leeway’ On Drug Use During Emergencies, Bright Hearing Shows

Executive Summary

In a Congressional hearing reminiscent of the right-to-try law debates, Democrats praised ousted BARDA Director Rick Bright for whistleblowing on the political interference in COVID-19 drug decisions, while Republicans argued the government should lower its standards during a pandemic and permit more widespread use of experimental medicines prior to clinical data. 

You may also be interested in...



Woodcock Said To Have Guided Hydroxychloroquine EUA In ‘Brokered Compromise’ To Limit Use

In whistleblower complaint, Rick Bright claims FDA Commissioner Hahn advocated for distributing hydroxychloroquine to pharmacies across the US, a departure from the approved emergency use authorization. Bright's complaint paints CDER Director Woodcock in a favorable light, saying she helped avoid an expanded access IND protocol for the potential coronavirus treatment.

US FDA Safety Alert For Hydroxychloroquine Is Latest Turn In Drug's Strange Journey

As potentially life-threatening heart problems emerge in coronavirus patients, FDA says hydroxychloroquine should be taken only in clinical trial or hospital settings under the Emergency Use Authorization.

BARDA Shake Up May Prompt Broad Review Of Politicization of Countermeasures Office

Rick Bright is requesting an inspector general investigation into his removal as director of the Biomedical Advanced Research and Development, accusing the Trump administration of favoring politics over science when making COVID-19 funding decisions. 

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS142202

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel